Biogen Inc. vs Pfizer Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Pfizer Inc. is the larger company by market value: $170.7 B against $37.5 B for Biogen Inc., 4.5 times as much (market caps of Oct 23, 2026 for Biogen Inc. and Oct 30, 2026 for Pfizer Inc.).
- Pfizer Inc. had more revenue: $62.6 B against $9.9 B for Biogen Inc., both in the year to December 2025.
- Pfizer Inc. earned more: net income of $7.8 B against $1.3 B for Biogen Inc.
- Biogen Inc. keeps more of each dollar of sales: a net margin of 13.1% against 12.4% for Pfizer Inc.
- Pfizer Inc. employs more people: 75,000 against 7,500 at Biogen Inc. Each employee brings in about $1,318,747 of revenue at Biogen Inc. and $834,387 at Pfizer Inc.
- On price to earnings, Biogen Inc. trades at 108.0× and Pfizer Inc. at 42.3×: investors pay more for each dollar of Biogen Inc.'s profit.
- Biogen Inc.'s revenue grew faster in its latest fiscal year: +2.2% against -1.6% for Pfizer Inc.
- On the Piotroski F-score, a nine-point test of improving finances, Biogen Inc. scores 4 and Pfizer Inc. 5.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Biogen Inc. BIIB · #692 in the world | Pfizer Inc. PFE · #127 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | Pharmaceutical |
| Founded | 1978 | 1849 |
| Size | ||
| Market cap | $37.5 B | $170.7 B |
| Revenue | $9.9 B | $62.6 B |
| Net income | $1.3 B | $7.8 B▲ best |
| Employees | 7,500 | 75,000 |
| Valuation | ||
| P/E ratio | 108× | 42.3× |
| Price to sales | 3.6× | 2.7× |
| Price to book | 2.1× | 2.0× |
| Free cash flow yield | 5.5%▲ best | 5.3% |
| Profitability | ||
| Gross margin | 75.7%▲ best | 74.3% |
| Net margin | 13.1%▲ best | 12.4% |
| Return on equity | 7.4% | 8.9%▲ best |
| Growth | ||
| Revenue growth | 2.2%▲ best | -1.6% |
| Revenue growth, 3 years a year | -0.9%▲ best | -14.8% |
| Earnings per share growth | -21.4% | -3.5%▲ best |
| Financial strength | ||
| Debt to equity | 0.3×▲ best | 0.7× |
| Cash | ||
| Free cash flow margin | 20.7%▲ best | 14.5% |
| Strength scores | ||
| Piotroski F-score | 4 of 9 | 5 of 9▲ best |
| Altman Z-score zone | — | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
Questions and answers#
Which is bigger, Biogen Inc. or Pfizer Inc.?
Pfizer Inc. is the larger company by market value: $170.7 B against $37.5 B for Biogen Inc., 4.5 times as much (market caps of Oct 23, 2026 for Biogen Inc. and Oct 30, 2026 for Pfizer Inc.).
Which makes more money, Biogen Inc. or Pfizer Inc.?
Pfizer Inc. had more revenue: $62.6 B against $9.9 B for Biogen Inc., both in the year to December 2025. Pfizer Inc. earned more: net income of $7.8 B against $1.3 B for Biogen Inc.
Which is more profitable, Biogen Inc. or Pfizer Inc.?
Biogen Inc. keeps more of each dollar of sales: a net margin of 13.1% against 12.4% for Pfizer Inc.
Which has more employees, Biogen Inc. or Pfizer Inc.?
Pfizer Inc. employs more people: 75,000 against 7,500 at Biogen Inc. Each employee brings in about $1,318,747 of revenue at Biogen Inc. and $834,387 at Pfizer Inc.
Is Biogen Inc. cheaper than Pfizer Inc.?
On price to earnings, Biogen Inc. trades at 108.0× and Pfizer Inc. at 42.3×: investors pay more for each dollar of Biogen Inc.'s profit. A lower multiple is not by itself a better buy: it also reflects expected growth, risk and accounting.
Which is growing faster, Biogen Inc. or Pfizer Inc.?
Biogen Inc.'s revenue grew faster in its latest fiscal year: +2.2% against -1.6% for Pfizer Inc.
Which is financially stronger, Biogen Inc. or Pfizer Inc.?
On the Piotroski F-score, a nine-point test of improving finances, Biogen Inc. scores 4 and Pfizer Inc. 5.